Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: Justification and rational implementation

Transfusion

Volumn 40, Issue 1, 2000, Pages 15-24

  Tabler, L H ^a,f   Tegtmeier, G ^b   Stramer, S L ^c   Qnan, S ^d   Dockter, J ^e   Giachetti, C ^f   Busch, M P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Division of New York Blood Center Enterprises   (United States)

^c National Confirmatory Testing Laboratory   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Gen Probe Incorporated   (United States)

^f Blood Centers of the Pacific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; ENZYME IMMUNOASSAY; HEALTH CARE POLICY; HEPATITIS C VIRUS; HUMAN; RECIPIENT; SCREENING; VIREMIA; VIRUS REACTIVATION;

BLOOD DONORS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MASS SCREENING; RECOMBINANT PROTEINS; RNA; TRIAGE;

EID: 0033957591     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40010015.x     Document Type: Article

References (17)

1. Busch MP. Let's look at human immunodeficiency virus look-back before leaping into hepatitis C virus look-back. Transfusion 1991:31:655-61.
2. Resolution of the HHS Advisory Committee on Blood Safety and Availability, August 11-12,1997 (available at www.hhs.gov/partner/bloodsafetyJ.
3. Guidance for industry: current Good Manufacturing Practice for blood and blood components: (1) quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2) supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV. Rockville, MD: Food and Drug Administration Center for Biologies Evaluation and Research (CBER), September 1998.
4. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal \Vkly Rep 1998;47 (RR-19):l-39.
5. Interagency Task Force Recommendations. Bethesda: American Association of Blood Banks, May 1998 (unpublished data).
6. Van der Poel CL, Reesink HW, Schaasberg W, et al. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 1990;335:558-60.
7. Aoki SK, Holland PV, Fernando LP, et al. Evidence of hepatitis in patients receiving transfusions of blood components containing antibody to hepatitis C. Blood 1993:82:1000-5.
8. Menitove JE, Richards \VA, Destree M. Early US experience with anti-HCVkit in blood donors. Lancet 1990:336:244-5.
9. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 1991:325:1325-9.
10. Kleinman S, Alter H, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992:32:805-13.
11. Nelson KE, Ahmed F, Stambolis V, et al. Incident hepatitis C virus (HCV) and hepatitis B virus (HBV) infections in transfused cardiac surgery patients: infection rates during different methods of donor screening (abstract). In: Program and abstracts book, NIH Consensus Development Conference on Infectious Disease Testing for Blood Transfusions 1995:67-9.
12. Van der Poel CL, Cuypers HT, Reesink HW, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991:337:317-9.
13. Evans CS, Tobler L, Polito A, et al. Comparative evaluation of supplemental hepatitis C virus antibody test systems. Transfusion 1992:32:408-14.
14. Hepatitis C: silent epidemic, mute public health response. Seventh Report by the Committee on Government Reform and Oversight. 105th Congress, second session. House Rep 105-820 (October 15, 1998).
15. McDonough SH, Giachetti C, Yang Y, et al. High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis type C virus (HCV). InfusionstherTransfusionsmed 1998;25:164-9.
16. Busch MP, Stramer SL, Kleinman S. Evolving applications of nucleic acid amplification assays for prevention of virus transmission by blood components and derivatives. In: Garratty G, ed. Applications of molecular biology to blood transfusion medicine. Bethesda: American Association of Blood Banks, 1997:123-76.
17. Lefrère JJ, Guiranmand S, Lefrère F, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997:175:316-22. d